Highlights of This Issue 1973

SPECIAL FEATURES

CCR 20th Anniversary Commentary

1975 CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
Sami I. Bashour and Nuhad K. Ibrahim

CCR Translations

1978 PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos
See related article, p. 2138

1981 The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
Saar Gill
See related article, p. 2020

CCR New Strategies

1984 New Strategies in Glioblastoma: Exploiting the New Biology
Howard A. Fine

Molecular Pathways

1989 Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Lynnette Fernandez-Cuesta and Roman K. Thomas

1995 Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy
Efficacy via Reduction in Oxygen Demand
Alexander Lin and Amit Maity

Reviews

2001 Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA)
cooporative study groups

2009 Genomic Landscape of Human Papillomavirus–Associated Cancers
Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

CANCER THERAPY: CLINICAL

2020 Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
See related commentary, p. 1981

PERSONALIZED MEDICINE AND IMAGING

2029 Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martin-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jiwon S. Samra, Anthony J. Gill, Nicole Watson, Venesa T. Chiu, Jeremy L. Humphritis, Angela Chou, Belinda Brown, Adrienne Money, Martina Pajic, Sean M. Grimmer, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blank, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGi) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

2038 Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Larigalerie

2045 Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek
CANCER THERAPY: PRECLINICAL

2057 MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller, Ghazaleh Tabatabai, Barbel Kastner, Jörg Fehberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platien, Jörg C. Tomm, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Kristizian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hising, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group

2065 PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen, Marcus M. Fischer, Fumiko Avelrod, Christopher Bond, Jennifer E. Amengual, Changchun Deng, Charles Karan, Ronald Realubit, Susan E. Bates, and Owen A. O’Connor

2096 Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

BIOLOGY OF HUMAN TUMORS

2107 Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Jasdeep K. Saggar and Ian F. Tannock

2115 Targeted Ax1 Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

2127 Rac1/Paki1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer

See related commentary, p. 1978

2138 PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

2148 The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
Gang An, Zengjun Li, Yu-Tzu Tai, Chiara Aghara, Qin Li, Xingqi Qin, Shuhua Yi, Yan Xu, Xiaoyan Feng, Chengwen Li, Jiawei Zhao, Lilui Shi, Meirong Zang, Shuhui Deng, Weiwei Sui, Mu Hao, Dehui Zou, Yaozhong Zhao, Junyuan Qi, Tao Cheng, Kun Ru, Jianxiang Wang, Kenneth C. Anderson, and Lugui Qiu

2157 Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Coloorectal Cancer
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, Alejandro Martinez, Israel Cañadas, Luca Lazzari, Noelia Fernuz, Mariangela Russo, Sandra Misale, Iria Gonzalez, Mar Iglesias, Elena Galván, Giorgio Corti, Sebastijan Hobor, Giovanni Cisafulli, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquín Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut
Table of Contents

2167 IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177 Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

2188 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION

2189 Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190 Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192 Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

LETTERS TO THE EDITOR

2187 RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.